SCHEMBL32690293

SCHEMBL32690293

Cc1ccc(Nc2ncc(Br)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)cc1N1CCN(C)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 7/20 0.59
ALK Q9UM73 10/20 0.54
MET P08581 3/20 0.54
CDK7 P50613 2/20 0.53
CDK9 P50750 1/20 0.53
INSR P06213 3/20 0.51
KCNH2 Q12809 2/20 0.51
PTK2 Q05397 3/20 0.49
AXL P30530 2/20 0.49
NEK2 P51955 2/20 0.49
BRD4 O60885 1/20 0.48
BMPR1B O00238 1/20 0.48
PLK4 O00444 1/20 0.48
STK25 O00506 1/20 0.48
RIOK3 O14730 1/20 0.48
CHEK1 O14757 1/20 0.48
CASK O14936 1/20 0.48
AURKA O14965 1/20 0.48
GAK O14976 1/20 0.48
DCLK1 O15075 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31251214 0.90 EGFR (0.61) EGFRALKMETCDK7CDK9
SCHEMBL32690395 0.83 CDK7 (0.53) EGFRALKMETCDK7CDK9
SCHEMBL31251194 0.83 CDK7 (0.53) EGFRALKMETCDK7CDK9
SCHEMBL31251235 0.81 ALK (0.54) EGFRALKMETCDK7CDK9
SCHEMBL31251139 0.80 CDK7 (0.53) EGFRALKMETCDK7CDK9
SCHEMBL31251379 0.80 CDK7 (0.52) ALKMETCDK7CDK9INSR
SCHEMBL25002639 0.79 ALK (0.55) EGFRALKMETCDK7CDK9
SCHEMBL13394913 0.79 ALK (0.74) EGFRALKMETCDK7INSR
SCHEMBL31251238 0.79 ALK (0.55) ALKMETCDK7CDK9PTK2
SCHEMBL31251128 0.79 CDK7 (0.54) ALKMETCDK7CDK9PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085050-A1 TRIPLE KINASE INHIBITORS UNOGEN BIOTECH LTD (US) 2026-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260085050-A1 TRIPLE KINASE INHIBITORS ALK, ERBB2, ERBB3 EGFR 4/4885ALK 1/4885MET 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.